PMC2804042_01
Spine MR showing the diffuse recurrent disease in the cervical spine (on the left) and the complete response during the treatment with bevacizumab (on the right).
JO2009-247873.001.jpg
PMC2804042_01_JO2009-247873.001.jpg
fig1
December 2006. During this period, the patient experienced a good quality of life and the progression-free interval was almost one year (Figure 1).